Thrombopoietin, the primary regulator of blood platelet production, was postulated to exist in
1958, but was only proven to exist when the cDNA for the hormone was cloned in 1994 …

Abstract Background Calcium (Ca2+) signaling regulates various vital cellular functions,
including integrin activation and cell migration. Store-operated calcium entry (SOCE) via …

Simple Summary Myeloproliferative neoplasms (MPNs) represent a group of blood cancers
characterized by the excessive production of blood cells in the bone marrow, including …

Hyperproliferation of myeloid and erythroid cells in myeloproliferative neoplasms (MPN)
driven by the JAK2-V617F mutation is associated with altered metabolism. Given the central …

Abstract Objectives The BCR:: ABL1 negative myeloproliferative neoplasms are sequentially
tested for JAK2 p. V617F, followed by CALR exon 9 pathogenic variants. Historically, these …

Momelotinib is an ATP-competitive small molecule inhibitor of Janus kinase proteins (JAKi),
including JAK1, JAK2, JAK3, and TYK2; its other clinically relevant targets include activin A …

Thromboembolic events and bleeding are known complications in essential
thrombocythaemia (ET) and polycythaemia vera (PV). Using multiple Swedish health care …

Hyperactivation of the NF-κB cascade propagates oncogenic signaling and proinflammation,
which together augments disease burden in myeloproliferative neoplasms (MPNs). Here, we …

Secondary acute myeloid leukemia (sAML) is a heterogeneous malignant hematopoietic
disease that arises either from an antecedent hematologic disorder (AHD) including …

Objective To evaluate the incidence, clinical laboratory characteristics, and gene mutation
spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR …